Editorial standards

Accurate about the product. Careful about health.

These standards apply to public CuraeVita website copy, app descriptions and supporting explanations. Last reviewed 29 August 2026.

01

Scope and responsibility

CuraeVita publishes product information about personal tracking tools. It does not publish personalised medical advice. Content is written to explain what an app records, what it sends, what it produces and where its limits lie.

02

Source hierarchy

Product claims are checked against the current app specification and implementation. Safety or platform guidance is checked against appropriate primary sources such as NHS, ICO, Android, Google Play or a service provider’s own documentation. Search summaries and marketing claims from unrelated sites are not treated as authority.

03

Health wording and claims

Copy distinguishes a record from an interpretation and an association from causation. CuraeVita does not claim that an app diagnoses a condition, determines treatment, proves a trigger, predicts a cycle, interprets laboratory results or calculates a prescribed dose unless a future regulated feature is specifically developed and substantiated.

04

Review process

Before release, pages are checked for feature accuracy, status, pricing, privacy statements, medical limitations, broken links and inconsistent wording. Material product changes should trigger a matching page review. Dates are shown where recency matters.

05

Commercial clarity

CuraeVita does not accept paid placement in its own app comparisons and does not use behavioural advertising SDKs in the Companions. Subscription prices, trial eligibility and renewal are shown by Google Play before purchase. Website copy identifies announced products separately from apps still in development.

06

Corrections and questions

If you find an inaccurate feature, privacy statement, status or link, email the page address and the specific issue. Corrections are prioritised according to their potential effect on health understanding, privacy or purchasing decisions.

Report a content issue